Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Harold Hileman

Internal Medicine Lebanon, IN Medical Doctor

NPI 1730129032 CMS profile 259611

2705 N Lebanon St Ste 315, Lebanon, IN 46052

Open in the dashboard

General payments

$17,261

696 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Harold Hileman of Lebanon, IN is reported in the CMS Open Payments database as having received $17,261 across 696 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,290 49
2024 General $3,008 158
2023 General $2,822 157
2022 General $2,538 129
2021 General $1,803 111
2020 General $904 31
2019 General $4,895 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Harold Hileman
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Harold Hileman were reported at $1,290. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Harold Hileman Internal Medicine median Middle half National median
2019 $4,895 $159 $48–$570 $163
2020 $904 $119 $33–$402 $114
2021 $1,803 $135 $37–$521 $132
2022 $2,538 $141 $42–$496 $149
2023 $2,822 $149 $45–$519 $160
2024 $3,008 $154 $47–$537 $164
2025 $1,290 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $4,776 123 payments
  2. AbbVie, Inc. $1,602 80 payments
  3. AstraZeneca Pharmaceuticals LP $1,336 35 payments
  4. Novo Nordisk Inc $1,141 47 payments
  5. Pfizer Inc. $1,029 44 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $939 36 payments
  7. GlaxoSmithKline, LLC. $910 50 payments
  8. Amgen Inc. $842 49 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $594 23 payments
  10. Janssen Pharmaceuticals, Inc $371 22 payments
  11. Other $3,719 187 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,238 692 payments
  2. Consulting Fee $3,000 1 payment
  3. Education $23 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,036 46 payments
  2. Kerendia $939 36 payments
  3. FARXIGA $796 14 payments
  4. MOUNJARO $762 40 payments
  5. UBRELVY $711 42 payments
  6. RYBELSUS $611 40 payments
  7. QULIPTA $605 32 payments
  8. EVENITY $575 33 payments
  9. Prolia $540 31 payments
  10. JARDIANCE $448 25 payments
  11. Other $10,999 544 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 89 drugs

Part D claims

5,004

Median for Internal Medicine: 777

Drug cost

$794,338

Median for Internal Medicine: $73,373

Branded share of claims

22.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 149 $227,115
Mounjaro Tirzepatide Brand 162 $202,795
Jardiance Empagliflozin Brand 90 $110,326
Eliquis Apixaban Brand 61 $50,251
Januvia Sitagliptin Phosphate Brand 29 $40,275
Kerendia Finerenone Brand 11 $16,252
Linzess Linaclotide Brand 17 $14,935
Spiriva Respimat Tiotropium Bromide Brand 21 $14,029
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 13 $12,040
Tresiba Flextouch U-200 Insulin Degludec Brand 13 $11,547

The 10 drugs with the highest cost, of 89 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$77,106

Of which drugs: $13,491

Medicare patients

199

Average age 77

Services billed

1,479

109 women, 90 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 41%
Diabetes 38%
Ischemic heart disease 33%
Chronic kidney disease 27%
Depression 22%
Atrial fibrillation 21%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 15 15 $4,335

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 44 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
$220 — —
JARDIANCE
$196 90 —
MOUNJARO
$191 162 —
Kerendia
$188 11 —
UBRELVY
$170 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 44 with Patron

Records

696 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record